Clinical

Articles

Data examining 4 low-value breast cancer procedures found an association between facility-level characteristics and the use of these procedures, suggesting a need for de-implementation targeting efforts in various facilities.

Significant Interfacility Variation Found in Implementation of Low-Value Breast Cancer Procedures

A retrospective, population-based cohort study in JAMA Oncology found Black women in the United States were more likely to have a high-risk recurrence score and die of axillary node-negative breast cancer than non-Hispanic White women who had similar scores.

Black Women With Node-Negative Breast Cancer More Likely to Have High-Risk Recurrence Scores Than Non-Hispanic White Women

In the OlympiA trial, patients with high-risk HER2-negative breast cancer were randomized 1:1 to receive either olaparib or placebo for 12 months.

Phase 3 OlympiA Trial for HER2-Negative Breast Cancer Moves to Early Primary Analysis Per IDMC Recommendation

Podcasts

CancerNetwork®’s podcast dissected a review article published in the journal ONCOLOGY® on the 21-gene recurrence score in patients with node-positive breast cancer.

Oncology Peer Review On-The-Go: Utility of 21-Gene Recurrence Score for Node-Positive Breast Cancer

ABSTRACT
The 21-gene Recurrence Score (RS) assay has been validated as both a prognostic and predictive tool in node-negative (pN0), estrogen receptor–positive (ER+), HER2-negative (HER2–) breast cancer. A large body of evidence supports the clinical utility of the RS in the node positive (pN+) population as well. Retrospective analyses of archived tissue from multiple clinical trials have found the RS to be prognostic in both endocrine therapy (ET)-treated and chemotherapy-treated patients with pN+ disease. Distribution of RS results in pN+ patients have also been consistent with those of pN0 populations. Data from the SWOG 8814 trial and large population-based registries further support the prognostic and potential predictive value of the RS. Specifically, patients with 1 to 3 positive nodes and RS less than 18 derived negligible benefit from adjuvant chemotherapy in these studies. In the prospective West German Study Group PlanB and ADAPT trials, pN+ patients with RS less than 11 and RS ≤25, respectively, who were treated with ET alone experienced excellent outcomes. Finally, 5-year results of the RxPONDER clinical trial randomizing patients with 1 to 3 positive nodes and RS ≤25 to ET alone vs ET plus chemotherapy confirmed an absence of chemotherapy benefit in postmenopausal patients. Clinical practice guidelines support use of the RS in the pN+, ER+/HER2– population, and many institutions have adopted the RS to guide clinical decision-making, resulting in a net reduction of adjuvant chemotherapy use. This review highlights the existing data supporting the prognostic and predictive ability of the RS in pN+ disease, current practice patterns related to RS use in this population, and emerging applications. 


Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer

The combination of palbociclib and endocrine therapy demonstrated a more favorable safety profile and improved quality of life versus capecitabine among patients with metastatic breast cancer who were resistant to aromatase inhibitors, despite not improving progression-free survival.

Palbociclib Plus Endocrine Therapy Is Less Toxic Than Standard Capecitabine for Treating AI-Resistant MBC

Investigators suggested that the results of this study may assist health care providers in personalized therapeutic regimen selections for patients with early-stage breast cancer.

DCE-MRI Successfully Predicts Axillary Lymph Node Metastasis, DFS in Early-Stage Breast Cancer

Videos

“We’re hearing about other antibody-drug conjugates, other agents in hormone receptor–positive metastatic disease, and the next generation of drugs that we’ll be using to treat our patients.”

Kevin Kalinsky, MD, MS, on Exciting Breast Cancer Treatments Coming Down the Pike

Imagio, a diagnostic tool that uses novel technology to provide real-time information on suspicious lesions in the breast, is OK’d by the FDA.

Optoacoustic Ultrasound Device for Assessing Breast Lesions Gets Premarket Approval

The Breast Cancer Index assay is the only of its kind to be recommended in the National Comprehensive Cancer Network Guidelines for the treatment of breast cancer as being predictive of extended adjuvant endocrine therapy.

Breast Cancer | Topics